Published in Pharma Law Weekly, June 20th, 2006
This patent-pending product is intended to deliver more consistent levels of the drug to patients who take the drug for chronic pain. Currently, there is no once-daily oxycodone on the market.
This is the second study for ELI-154 and the company's second oxycodone HCl product in clinical trials. The first pilot Phase I study for this product demonstrated proof of concept. This second study will evaluate variables to optimize the formulation. Upon completion of this study, Elite intends to enter into a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly